Two Paths: Device Reforms In Senate, House Bills Differ Dramatically
This article was originally published in The Gray Sheet
Companies should expect much more in the way of FDA reforms than what is contained in the core user fee agreements. The chart compares provisions in the latest available versions of House and Senate bills.
You may also be interested in...
Legislation was reported out of committee last week, with some additional amendments under consideration as the user fee reauthorization bill moves closer to the Senate floor. House members still struggle to reach consensus.
Oxford University/AstraZeneca’s COVID-19 vaccine cuts the spread of the virus by 60%, apart from having 70% efficacy in reducing infections in vaccinated individuals. While that is good news for their Indian partner, Serum Institute, the 90% efficacy shown in a subset due to a dosing error causes a dilemma.